

Regd Office: "Jupiter Hospital", Opp. ICAI Bhawan, Sun Pharma Ataladra Road, Vadodara – 390012, Gujarat, India, Email: info@jupiterhospitalvadodara.com; CIN: L85100GJ2014PLC079062, Website: www.jupiterhospitalvadodara.com, Contact No: 0265 2681568 / NSE Symbol: AATMAJ / ISIN: INEOOB201016 / Segment: SME

AHL/NSE/11/24 November 12, 2024

The Manager, Listing Department National Stock Exchange of India Limited Exchange Plaza, 5th Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (E), Mumbai - 400 051, Maharashtra, India.

Symbol: AATMAJ / ISIN: INE00B201016

Segment: SME

Dear Sir/Madam,

Sub: Outcome of Board meeting held on today i.e. Tuesday, November 12, 2024, in terms of Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Pursuant to the Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors of the Company, at their Board Meeting held on today, i.e. Tuesday, November 12, 2024, at the Registered Office of the Company situated at "Jupiter Hospital", Opp. ICAI Bhawan, Sun Pharma Ataladra Road, Vadodara – 390012, Gujarat, India and which was commenced at 05.00 pm and concluded at 05.45 pm has inter-alia considered and approved the following:

 Considered, approved and taken on record the Standalone Un-audited Financial Results of the Company for the half year ended September 30, 2024 along with Limited Review Report of the Auditors' thereon;

The said Financial Statements / Results were reviewed and recommended by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held today.

2. Considered and approved all other business as per agenda circulated.

Kindly take the above on record and oblige us.

Thanking you. Yours faithfully,

For Aatmaj Healthcare Limited

SUVAGIYA
TUSHAR
KARSHANBHAI
KARSHANBHAI
Digitally signed by
SUVAGIYA TUSHAR
KARSHANBHAI
Dojtet 2024.11.12
17:50:42 +05'30'

Tushar K Suvagiya Managing Director DIN: 06802410

Encl: As Stated Above



Regd Office: "Jupiter Hospital", Opp. ICAI Bhawan, Sun Pharma Ataladra Road, Vadodara – 390012, Gujarat, India, Email: info@jupiterhospitalvadodara.com; CIN: L85100GJ2014PLC079062, Website: www.jupiterhospitalvadodara.com, Contact No: 0265 2681568 / NSE Symbol: AATMAJ / ISIN: INEOOB201016 / Segment: SME

AHL/NSE/11/24 November 12, 2024

The Manager, Listing Department National Stock Exchange of India Limited Exchange Plaza, 5th Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (E), Mumbai - 400 051, Maharashtra, India.

Symbol: AATMAJ / ISIN: INE0OB201016

Dear Sir/Madam,

Sub: Submission of Standalone Un-Audited Financial Results of the Company for the half year ended September 30, 2024 along with Limited Review Report of the Auditors' thereon.

Ref: Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

With reference to captioned subject and pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Standalone Un-audited Financial Results of the Company for the half year ended September 30, 2024 alongiwth Limited Review Report of the Auditors' thereon.

The said Financial Statements / Results were reviewed and recommended by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held today.

Kindly take the above on record and oblige us.

Thanking you.
Yours faithfully,
For Aatmaj Healthcare Limited

SUVAGIYA Digitally signed by SUVAGIYA TUSHAR KARSHANBHAI CHARSHANBHAI (ARSHANBHAI (ARSHANB

Tushar K Suvagiya Managing Director DIN: 06802410

Encl: As Stated Above

Bela Mehta and Associates

CHARTERED ACCOUNTANTS



(Office Address: A-204, Shree Siddhi Vinayak Complex, Opp. Railway Station (West Side), Alkapuri – Vadodara – 390 007. Gujarat, India / Email: parikh.shital@gmail.com)

Limited Review Report on the Unaudited Standalone Financial Results of Aatmaj Healthcare Limited pursuant to the regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the half year ended September 30, 2024

To
The Board of Directors of
Aatmaj Healthcare Limited
CIN: L85100GJ2014PLC079062
"Jupiter Hospital", Opp. ICAI Bhawan,
Sun Pharma Ataladra Road,
Vadodara – 390012, Gujarat, India

- 1. We have reviewed the accompanying statement of Unaudited Standalone Financial Results of **Aatmaj Healthcare Limited** ("the Company"), for the half year ended September 30, 2024 ("the Statement") being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (the "Listing Regulations").
- 2. This Statement which is responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard 25 "Interim Financial Reporting" (As 25), prescribed under section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in compliance with Regulation 33 of listing regulations. Our responsibility is to issue a report on this Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform our review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquires of company personnel analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express and audit opinion.
- 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited standalone financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatements.

For Bela Mehta and Associates

Chartered Accountants

FRN: 101073W

Shital S Parikh M.No.: 121609

UDIN: 24121609BKGXNQ1231



Regd Office: "Jupiter Hospital", Opp. ICAI Bhawan, Sun Pharma Ataladra Road, Vadodara – 390012, Gujarat, India, Email: info@jupiterhospitalvadodara.com; CIN: L85100GJ2014PLC079062, Website: www.jupiterhospitalvadodara.com, Contact No : 0265 2681568

Statement of Unaudited Standalone Financial Results for the Half Year ended on 30.09.2024


(Rs. In Lakhs)

Particulars		For the year ended		
	30.09.2024 Unaudited	31.03.2024 Audited (Refer Note 3)	30.09.2023 Unaudited	March 31, 2024 Audited
Revenue from operations	850.80	717.17	856.64 23.60	1,573.81 84.68
Other income Total Revenue Expenses	75.72 926.52	778.25	880.24	1,658.49
Cost of Materials Consumed	135.29	174.69	71.73	246.42
Purchases of Stock-in-Trade	-	-	-	-
Changes in Inventories of Finished Goods, work-in-progress and Stock-in-Trade	-		-	•
Employee Benefits Expense	238.17	241.52	115.33	356.85
Finance costs	37.46	66.23	58.68	124.9
Depreciation and Amortization Expense	47.09	42.78	38.06	80.84
Other Expenses	435.70	433.09	282.11	715.20
Total Expenses	893.71	958.31	565.91	1,524.22
Profit Before Tax	32.81	(180.06)	314.33	134.27
Tax expense:		(45.00)	77.00	32.00
Current tax	2.17	5.47	8.72	14.19
Deferred tax Profit/(loss) for the period	30.64	(140.53)	228.61	88.08
Earnings per equity share:				
Basic	0.14	(0.62)	1.01	0.39
Diluted	0.14	(0.62)	1.01	0.39

On Behalf of the Board, For Aatmaj Healthcare Limited

Tushar K Suvagiya Managing Director DIN: 06802410







Regd Office: "Jupiter Hospital", Opp. ICAI Bhawan, Sun Pharma Ataladra Road, Vadodara – 390012, Gujarat, India, Email: info@jupiterhospitalvadodara.com; CIN: L85100GJ2014PLC079062, Website: www.jupiterhospitalvadodara.com, Contact No : 0265 2681568

Notes attached to Unaudited Standalone Financial Results for the Half Year ended September 30, 2024

- The above standalone financial results of the company ("the statement") have been reviewed by the Audit
 Committee and subsequently approved by the Board of Directors of the Company at its Meeting held on
 November 12, 2024 and have been subjected to limited review by the statutory auditors of the company
 on which the auditors have been expressed an unmodified Opinion.
- 2. The Standalone Financial results has been prepared in accordance with recognition and measurement principles laid down in the Accounting Standard 25 "Interim Financial Reporting" (As 25) as prescribed under section 133 of the companies act, 2013 ("the Act") read with the companies (accounting standards) Rules, 2021, as amended from time to time and other accounting principal generally accepted in India.
- The figures for the Half year ended March 31, 2024 are the balancing figures between audited figures in respect of year ended March 31, 2024 and figures for the half year ended September 30, 2023.
- 4. The company is engaged primarily in the business of Operating Multi Speciality Hospitals and all its operations are in India only. Accordingly, there is no separate reportable segment as per AS 17 on "Segment Reporting" in respect of Company.
- 5. The Company applied to National Stock Exchange of India Limited ("NSE") for in-principle approval for listing its equity shares on the Emerge Platform of the NSE. National Stock Exchange of India Limited has, vide its letter dated June 1, 2023 granted it's In Principle Approval to the Company. The Company had filed Prospectus to the Registrar of the Company, Ahmedabad on June 13, 2023. The Public Issue was opened on Monday, June 19, 2023 and closed on Wednesday, June 21, 2023. The Basis of Allotment was finalized by Company, Registrar to the issue and merchant banker in consultation with the NSE on June 26, 2023. The Company has applied for listing of its total equity shares to NSE and it has granted its approval vide its letter dated June 28, 2023. The trading of equity shares of the Company commenced w.e.f. June 30, 2023 at Emerge Platform of National Stock Exchange of India Ltd. (NSE). The details of utilisation of the IPO Proceeds as below upto 30/09/2024.

[Amount Rs. In Lakhs]

Sr. No.	Objects as per Prospectus (Offer Document)	Amount disclosed in Offer Document	Actual Utilised amount as on 30/09/2024	Unutilised Amount as on 30/09/2024	Remarks
1	Repayment/Prepayment in full or part of existing secured debt of the Company.	900.00	900.00	-	
2	Funding the working capital requirements of the Company.	600.00	600.00	-	
3	Purchase of medical equipments for hospitals of our Company and/or newly acquired or set up hospitals.*	913.11		913.11	Kept as FDR with Bank as on 30/09/2024
4	Company's inorganic growth initiatives through acquisitions and other strategic initiatives.	620.00	620.00		
5	General Corporate Expenses	496.89	496.89	•	
6	Issue Expenses	310.00	310.00	-	
-	Total Rs. In Lacs	3,840.00	2,926.89	913.11	





Regd Office: "Jupiter Hospital", Opp. ICAI Bhawan, Sun Pharma Ataladra Road, Vadodara – 390012, Gujarat, India, Email: info@jupiterhospitalvadodara.com; CIN: L85100GJ2014PLC079062, Website: www.jupiterhospitalvadodara.com, Contact No : 0265 2681568

*Notes: (i) The Board of Directors of the Company sought an approval of the Members by way of Special Resolution dtd. July 03, 2024 for variation in terms of the Object of the issue of the prospectus dtd. June 13, 2023, for utilising IPO proceeds amounting to Rs. 913.11 Lakhs for Working capital requirements of the company in lieu of Purchase of medical equipments for hospitals and/or newly acquired or set up hospitals. (ii) The Special Resolution proposed for Members approval for variation in terms of the Object of the issue of the prospectus for utilising IPO Proceeds by way of Postal Ballot Notice Dtd. May 25, 2024 through remote e-voting. (iii) The remote e-voting for Members' approval by way of Special Resolution proposed was remained open for a period of thirty days which was commenced at 9:00 A.M. on Tuesday, June 4, 2024 and ended on 5:00 P.M. on Wednesday, July 3, 2024. (iv) The Special Resolution proposed as mentioned above was approved by Members with majority. (v) A Scrutinizer's report dtd. July 05, 2024, i.e. outcome of e-voting Results, was submitted by the Company to NSE on July 05, 2024, in compliance with the Listing Agreement. (vi) The Company has kept the unutilised amount of IPO Proceeds as mentioned above as FDR with the Bank for the period ended September 30, 2024.

- 6. Unaudited statements of Assets and liabilities and Statement of Cash Flow are attached as "Annexure A' and "Annexure B" respectively.
- 7. Previous year's/period's figures have been regrouped/reclassified whenever necessary.

On Behalf of the Board, For Aatmaj Healthcare Limited

Tushar K Suvagiya Managing Director DIN: 06802410





Regd Office: "Jupiter Hospital", Opp. ICAI Bhawan, Sun Pharma Ataladra Road, Vadodara – 390012, Gujarat, India, Email: info@jupiterhospitalvadodara.com; CIN: L85100GJ2014PLC079062, Website: www.jupiterhospitalvadodara.com, Contact No : 0265 2681568

Annexure A: Standalone Statement of Assets and Liabilities

(Rs. In Lakhs)

Particulars	As at September 30, 2024	As at March 31, 2024
EQUITY AND LIABILITIES		
Shareholders' Funds		
Share capital	1,130.00	1,130.00
Reserves and surplus	3,848.86	3,818.22
	4,978.86	4,948.22
Non-Current Liabilities	100 60	124.00
Long-term borrowings	100.68	81.36
Deferred Tax Liabilities (Net)	03.33	01.50
Other Long-term liabilities Long-term provisions		-
Long-term provisions	184.21	205.36
Commont Linbilities		
Current Liabilities Short Term Borrowings	901.19	423.87
Trade payables	37.50	132.01
Other Current Liabilities	11.16	6.17
Short Term Provisions	40.61	52.77
	990.46	614.82
TOTAL	6,153.53	5,768.40
ASSETS		
Non-Current Assets		
Property, Plant and Equipment		4 254 72
Tangible assets	1,249.21	1,251.72
Intangible assets	564.23	566.16
Capital work-in-progress		
Intangible assets under development	1,813.44	1,817.88
Non gurrant investments	1,013.44	1,017.00
Non-current investments Long-term loans and advances		_
Other non-current assets		-
Other Horr carrette assets	1,813.44	1,817.88
Current assets		
Inventories	60.70	64.10
Trade receivables	2,230.02	2,061.68
Cash and cash equivalents	1,161.23	1,080.91
Short-term loans and advances	803.54	688.28
Other current assets	84.60	55.55
	4,340.09	3,950.52
TOTAL	6,153.53	5,768.40

On Behalf of the Board, For Aatmaj Healthcare Limited

Tushar K Suvagiya Managing Director DIN: 06802410





Regd Office: "Jupiter Hospital", Opp. ICAI Bhawan, Sun Pharma Ataladra Road, Vadodara – 390012, Gujarat, India, Email: info@jupiterhospitalvadodara.com; CIN: L85100GJ2014PLC079062, Website: www.jupiterhospitalvadodara.com, Contact No : 0265 2681568

ANNXURE B - STANDALONE CASH FLOW STATEMENT

(Rs. In Lakhs)

(1.51 = 1. = 5.					
Particular	For the Half year ended September 30, 2024	For the year ended March 31, 2024			
Cash Flows from Operating Activates					
Net Profit Before Tax and Extra Ordinary Items	32.81	134.27			
Adjustment For					
Depreciation	47.09	80.84			
Finance Cost	37.46	124.91			
	117.36	340.02			
Adjustment For working Capital Change					
(Increase)/Decrease in Inventories	3.40	(24.05)			
(Increase)/Decrease in Trade Receivables	(168.34)	(279.07)			
(Increase)/Decrease in Other Current Assets	(144.31)	(614.55)			
Increase/(Decrease) in Trade Payable	(94.51)	(79.94)			
Increase/(Decrease) in other current Liabilities	4.99	(2.81)			
Increase/(Decrease) in Provisions	(12.16)	(172.25)			
Total Adjustment For Working Capital	(410.93)	(1,172.67)			
Net Cash flow from (Used in)/Generated from	(293.57)	(832.65)			
operation					
Less: Income Tax Paid/ Refund	i e	(32.00)			
Net Cash flow From operating Activities	(293.57)	(800.65)			
Cash Flows from Investing Activities					
Purchase of Fixed Assets	(42.62)	(781.64)			
Purchase of Investments or Equity Instruments	_	-			
Deposits Given	_	*			
Net Cash flow Used in in Investing Activities	(42.62)	(781.64)			
Cash Flows from Financial Activities					
Proceeds From Issuing Shares	-	3,432.37			
Proceeds From Borrowing	-				
Repayment of Borrowing	(23.35)	(675.94)			
Increase/(Decrease) in short term Borrowings	477.32	-			
Finance Cost	(37.46)	(124.91)			
Net Cash flow from (Used in) in Financial Activities	416.51	2,631.52			
Net increase (decrease) in cash and cash equivalents	80.32	1,049.23			
Cash and cash equivalents at beginning of period	1,080.91	31.68			
Cash and cash equivalents at end of period	1,161.23	1,080.91			

On Behalf of the Board, For Aatmaj Healthcare Limited

Tushar K Suvagiya Managing Director DIN: 06802410

